Clinical Trial Update: BufferGel and PRO 2000/5: Vaginal Gels to Prevent HIV Infection in Women [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for vaginal gels BufferGel and PRO 2000/5 aimed at preventing HIV infection in women; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• BufferGel
• PRO 2000/5

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 2 | Status: COMPLETED